Phase I trial of docetaxel plus lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 (

Aged Aged, 80 and over Antibodies, Monoclonal / administration & dosage Antineoplastic Agents / administration & dosage Antineoplastic Combined Chemotherapy Protocols / administration & dosage Docetaxel / administration & dosage Humans Male Maximum Tolerated Dose Middle Aged Neoplasm Metastasis Prospective Studies Prostatic Neoplasms, Castration-Resistant / drug therapy
Chemotherapy Prostate cancer Prostate-specific membrane antigen Radioimmunotherapy

Journal

Urologic oncology
ISSN: 1873-2496
Titre abrégé: Urol Oncol
Pays: United States
ID NLM: 9805460

Informations de publication

Date de publication:
11 2020
Historique:
received: 05 03 2020
revised: 26 05 2020
accepted: 28 05 2020
pubmed: 1 7 2020
medline: 13 8 2021
entrez: 1 7 2020
Statut: ppublish

Résumé

Docetaxel remains a standard of care for metatsatic castration resistant porstate cancer (mCRPC) and has radiosensitizing properties. The dose limiting toxicity (DLT) of radioimmunotherapy is myelosuppression; dose fractionation of Men with progressive mCRPC received docetaxel 75 mg/m Fifteen men with progressive mCRPC received dose-escalated targeted radionuclide therapy in 4 cohorts up to the highest planned dose (2.96 GBq/m The combination of

Sections du résumé

BACKGROUND
Docetaxel remains a standard of care for metatsatic castration resistant porstate cancer (mCRPC) and has radiosensitizing properties. The dose limiting toxicity (DLT) of radioimmunotherapy is myelosuppression; dose fractionation of
METHODS
Men with progressive mCRPC received docetaxel 75 mg/m
RESULTS
Fifteen men with progressive mCRPC received dose-escalated targeted radionuclide therapy in 4 cohorts up to the highest planned dose (2.96 GBq/m
CONCLUSION
The combination of

Identifiants

DOI: 10.1016/j.urolonc.2020.05.028 PMID: 32600929
pubmed: 32600929
pii: S1078-1439(20)30259-3
doi: 10.1016/j.urolonc.2020.05.028
pii:
doi:

Substances chimiques

Antibodies, Monoclonal 0
Antineoplastic Agents 0
J591 monoclonal antibody 0
Docetaxel 15H5577CQD

Types de publication

Clinical Trial, Phase I Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

848.e9-848.e16

Informations de copyright

Copyright © 2020 The Author(s). Published by Elsevier Inc. All rights reserved.

Auteurs

Jaspreet S Batra (JS)

Department of Urology, Weill Cornell Medicine, New York, NY.

Muhammad Junaid Niaz (MJ)

Department of Urology, Weill Cornell Medicine, New York, NY.

Young E Whang (YE)

Department of Medicine, Division of Hematology/Oncology, University of North Carolina School of Medicine, Chapel Hill, NC.

Arif Sheikh (A)

Department of Radiology, Icahn School of Medciine at Mount Sinai, New York, NY.

Charlene Thomas (C)

Department of Biostatistics and Epidemiology, Weill Cornell Medicine, New York, NY.

Paul Christos (P)

Department of Biostatistics and Epidemiology, Weill Cornell Medicine, New York, NY.

Shankar Vallabhajosula (S)

Division of Molecular Imaging and Therapeutics, Department of Radiology, Weill Cornell Medicine, New York, NY.

Yuliya S Jhanwar (YS)

Division of Molecular Imaging and Therapeutics, Department of Radiology, Weill Cornell Medicine, New York, NY.

Ana M Molina (AM)

Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medicine, New York, NY; Meyer Cancer Center, Weill Cornell Medicine, NewYork Presbyterian Hospital, New York, NY.

David M Nanus (DM)

Department of Urology, Weill Cornell Medicine, New York, NY; Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medicine, New York, NY; Meyer Cancer Center, Weill Cornell Medicine, NewYork Presbyterian Hospital, New York, NY.

Joseph R Osborne (JR)

Division of Molecular Imaging and Therapeutics, Department of Radiology, Weill Cornell Medicine, New York, NY; Meyer Cancer Center, Weill Cornell Medicine, NewYork Presbyterian Hospital, New York, NY.

Neil H Bander (NH)

Department of Urology, Weill Cornell Medicine, New York, NY; Meyer Cancer Center, Weill Cornell Medicine, NewYork Presbyterian Hospital, New York, NY.

Scott T Tagawa (ST)

Department of Urology, Weill Cornell Medicine, New York, NY; Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medicine, New York, NY; Meyer Cancer Center, Weill Cornell Medicine, NewYork Presbyterian Hospital, New York, NY. Electronic address: stt2007@med.cornell.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › Phase I trial of docetaxel plus...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › Sujet âgé de 80 ans ou plus › Phase I trial of docetaxel plus...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps monoclonaux › Phase I trial of docetaxel plus...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Antinéoplasiques › Phase I trial of docetaxel plus...
questionsmedicales.fr › Thérapeutique › Traitement médicamenteux › Association de médicaments › Protocoles de polychimiothérapie antinéoplasique › Phase I trial of docetaxel plus...
questionsmedicales.fr › Composés chimiques organiques › Hydrocarbures › Terpènes › Diterpènes › Taxoïdes › Docetaxel › Phase I trial of docetaxel plus...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Phase I trial of docetaxel plus...
questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Phénomènes toxicologiques › Dose maximale tolérée › Phase I trial of docetaxel plus...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Adulte d'âge moyen › Phase I trial of docetaxel plus...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Processus néoplasiques › Métastase tumorale › Phase I trial of docetaxel plus...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études prospectives › Phase I trial of docetaxel plus...
questionsmedicales.fr › Maladies urogénitales › Tumeurs de l'appareil urogénital › Tumeurs de l'appareil génital mâle › Tumeurs de la prostate › Tumeurs prostatiques résistantes à la castration › Phase I trial of docetaxel plus...